


**Claims without indication of amendments**

1. Use of a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis.
2. Use according to claim 1, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.
3. Use according to claim 1 or 2, whereby said simmondsin is selected from the group comprising 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4,5-dimethylsimmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or any mixtures thereof.
4. Use according to any of claims 1-3 wherein said esters are ferulates.
5. Use according to any of claims 1-4, whereby said simmondsin is selected from the group comprising 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.
6. Use of a compound having general formula (I)



Formula (I)

and stereoisomeric forms, racemic mixtures, metabolites, esters, salts, or mixtures thereof, for the manufacture of a medicament for inhibiting angiogenesis,

wherein  $R_4$  and  $R_5$  are independently selected from the group comprising oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkylthiocarbonyl, alkanoyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkanoyl, cycloalkylthiocarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkoxythiocarbonyl, cycloalkylthioalkyl,

alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, cycloalkylcarbonyloxyalkyl, silyloxyalkyl, aryl, aralkyl, arylalkenyl, arylcarbonyl, aryloxycarbonyl, arylthiocarbonyl, aralkoxycarbonyl, arylalkylthiocarbonyl, aryloxyalkyl, arylthioalkyl, haloalkyl, hydroxyalkyl, aralkanoyl, aroyl, aryloxycarbonylalkyl, aryloxyalkanoyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoyl, aminoalkyl,  $CR^6=NR^7$  or  $CR^6=N(OR^7)$ , with  $R^6$  and  $R^7$  being independently selected from the group comprising hydrogen, hydroxyl, alkyl, aryl, alkenyl, alkynyl, aminoalkyl, aminoaryl, alkylcarbonylamino, arylcarbonylamino, alkylthiocarbonylamino and arylthiocarbonylamino; and

wherein  $R_3$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_6$  are independently selected from the group comprising hydroxyl or an ester.

7. Use of a compound having general formula (I) according to claim 6, wherein  $R_4$  and  $R_5$  are independently selected from the group comprising oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkylthiocarbonyl, alkanoyl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, silyloxyalkyl, haloalkyl, hydroxyalkyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoyl, aminoalkyl, and wherein  $R_3$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_6$  are independently selected from the group comprising hydroxyl or an ester.

8. Use of a compound having general formula (I) according to claim 6 or 7, wherein  $R_4$  and  $R_5$  are independently selected from the group comprising hydroxyl, alkyl, alkyloxy, and wherein  $R_3$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_6$  are independently selected from the group comprising hydroxyl or an ester.

9. Use of a compound having general formula (I) according to any of claims 6-8, wherein  $R_4$  and  $R_5$  are independently selected from the group comprising hydroxyl, and  $-OCH_3$ , and wherein  $R_3$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_6$  are independently selected from the group comprising hydroxyl or an ester.

10. Use of a compound having general formula (I) according to any of claims 6-9, wherein said ester is a ferulate.

11. Use of a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or mixtures thereof for the manufacture of a medicament for treating angiogenesis-related diseases.

12. Use according to claim 11, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.

13. Use according to claims 11 or 12, whereby said simmondsin is selected from the group comprising 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.

14. Use of a compound having general formula (I) as defined in claim 6, for the manufacture of a medicament for treating angiogenesis-related diseases.

15. A simmondsin having general formula (I), as defined in claim 6, with the exception of 4,5-dimethylsimmondsin and 4,5-dimethylsimmondsin-2'-ferulate for use as a medicament.

16. Use of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5 didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, and 4,5-didesmethylsimmondsin-2'-ferulate, as a medicament.

17. Polar extract from jojoba flour for use as a medicament.

18. Use of jojoba flour or an extract from jojoba flour for the manufacture of a medicament for inhibiting angiogenesis.

19. Use of jojoba flour or an extract from jojoba flour for the manufacture of a medicament for treating angiogenesis-related diseases.

20. A pharmaceutical composition for inhibiting angiogenesis or for treating angiogenesis-related diseases comprising a therapeutically effective amount of a compound as defined in claim 6 with the exception of 4,5-dimethylsimmondsin and 4,5-dimethylsimmondsin-2'-ferulate and a pharmaceutically acceptable excipient.

21. Pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied orally.

22. Pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied parentally.

23. Pharmaceutical composition according to claim 20, wherein said pharmaceutical composition

is formulated to be applied topically.

24. Method of inhibiting angiogenesis in humans and animals comprising administering to the human or animal in need thereof a therapeutically effective amount of a compound as defined in claim 6.

25. Method of treating an angiogenesis-related disease in humans and animals comprising administering to the human or animal in need thereof a therapeutically effective amount of a compound as defined in claim 6.